FDA Should Validate Risk Management Tools’ Effectiveness, PhRMA Says
This article was originally published in The Tan Sheet
Executive Summary
FDA risk management programs should be evaluated by the agency to determine their value, the Pharmaceutical Research & Manufacturers of America maintained during a public workshop on risk management in Washington, D.C. April 10